论文部分内容阅读
目的:建立测定大鼠血浆中藤黄酸葡萄糖酯浓度的UPLC方法,并探讨其在大鼠体内的药代动力学。方法:以新藤黄酸为内标,建立大鼠血浆中藤黄酸葡萄糖酯的UPLC测定方法。采用该方法测定大鼠单剂量静脉注射2、4、8 mg/kg藤黄酸葡萄糖酯后,不同时间点大鼠血浆中的藤黄酸葡萄糖酯的浓度,对其血药浓度-时间采用DAS 2.1软件拟合,计算药动学参数。结果:血浆中藤黄酸葡萄糖酯在0.05~14.0 mg/L浓度范围内线性关系良好(r=0.9999),定量下限为0.05 mg/L,提取回收率均大于87%,其日内日间RSD均小于10%,藤黄酸葡萄糖酯按2、4和8 mg/kg静脉给药后,在大鼠体内的t1/2分别为(16.66±1.56)、(16.81±2.21)和(17.88±2.05)min,AUC0-t分别为(12.92±13.14)、(37.3±18.58)和(68.22±20.91)min·mg·L-1。结论:所建立的UPLC方法操作简便、快速、专属性强,能满足藤黄酸葡萄糖酯在大鼠体内的药代动力学研究。
OBJECTIVE: To establish an UPLC method for the determination of glucose in rat plasma and to study its pharmacokinetics in rats. Methods: Using UPGC as internal standard, UPLC method was established for determination of glucose in human rat plasma. The method was used to determine the concentration of glucose in rat plasma at a single dose of 2, 4, and 8 mg / kg of glucose acetate, and the plasma concentrations of D-glucose 2.1 software fitting, calculation of pharmacokinetic parameters. Results: There was a good linearity (r = 0.9999) in the concentration range of 0.05-14.0 mg / L, and the lower limit of quantitation was 0.05 mg / L in the plasma. The average recoveries were both higher than 87% (16.66 ± 1.56), (16.81 ± 2.21) and (17.88 ± 2.05), respectively, in rats after intravenous administration of 2,4, and 8 mg / kg of glucose acetate, min and AUC0-t were (12.92 ± 13.14), (37.3 ± 18.58) and (68.22 ± 20.91) min · mg · L-1, respectively. Conclusion: The established UPLC method is simple, rapid and specific, and can meet the pharmacokinetics of glucose acetate in rats.